Sarveshwar Foods Delivers Robust 9M FY26 Performance; Revenue at ₹966.43 Crore, Net Profit Jumps 33.44%

Jammu (Jammu & Kashmir) [India], February 16: Sarveshwar Foods Limited, (SFL | BSE – 543688 | INE324X01026), one of India’s leading agro and organic FMCG companies, has announced its Unaudited Financial Results for Q3 & 9M FY26.

Key Financial Highlights

9M FY26 Consolidated Financial Highlights

  • Total Income of ₹ 966.43 Cr, YoY growth of 22.45%
  • EBITDA of ₹ 54.42 Cr, YoY growth of 4.96%
  • EBITDA Margin (%) of 5.63%, YoY down by 94 Bps
  • Net Profit of ₹ 24.47 Cr, YoY growth of 33.44%
  • Net Profit Margin (%) of 2.53%, YoY up by 21 Bps

Q3 FY26 Consolidated Financial Highlights

  • Total Income of ₹ 328.58 Cr, YoY growth of 16.07%
  • EBITDA of ₹ 18.64 Cr, YoY decline by 1.07%
  • EBITDA Margin (%) of 5.67%, YoY decline by 98 Bps
  • Net Profit of ₹ 9.22 Cr, YoY growth of 30.23%
  • Net Profit Margin (%) of 2.81%, YoY up by 31 Bps

9M FY26 Standalone Financial Highlights

  • Total Revenue of ₹ 466.34 Cr, YoY growth of 16.47%
  • EBITDA of ₹ 23.13 Cr, YoY decline by 0.74%
  • EBITDA Margin (%) of 4.96%, YoY decline by 86 Bps
  • Net Profit of ₹ 9.98 Cr, YoY growth of 32.79%
  • Net Profit Margin (%) of 2.14%, YoY up by 26 Bps

Q3 FY26 Standalone Financial Highlights

  • Total Revenue of ₹ 159.75 Cr, YoY growth of 9.92%
  • EBITDA of ₹ 6.96 Cr, YoY decline by 22.83%
  • EBITDA Margin (%) of 4.35%, YoY down by 185 Bps
  • Net Profit of ₹ 3.38 Cr, YoY growth of 4.95%
  • Net Profit Margin (%) of 2.12%, YoY decline by 10 Bps

Commenting on the financial performance, Mr. Rohit Gupta, Chairman, Sarveshwar Foods Limited, said: “We take genuine pride with the performance we have delivered during the first nine months of FY26. Crossing ₹966 crore in revenue and delivering 33% growth in net profit is not just a financial milestone, but a reflection of the resilience of our business and the commitment of our teams and partners. Even in a volatile commodity environment, we stayed focused on strengthening our fundamentals by improving realizations, sharpening our product mix, and maintaining financial discipline. This balanced approach is helping us build a business that is not only growing, but becoming stronger and more resilient with each quarter.

What excites us even more is the opportunity ahead. The global appetite for premium basmati rice continues to expand, and consumers are increasingly shifting toward trusted, branded and organic food choices. With our strong sourcing base in Jammu and Kashmir, an expanding branded portfolio under Nimbark, and a growing presence across exports and digital channels, we believe we are entering a phase of meaningful scale. We remain confident, ambitious and committed to creating long-term value while steadily enhancing margins and strengthening our brand equity in the years ahead.”

If you object to the content of this press release, please notify us at [email protected]. We will respond and rectify the situation within 24 hours.

aayush jain acquisition Business cashew processing cote d’ivoire esos 2026 pacific global fzco Pajson Agro pulkit jain Royal Mewa Share Swap

From Local to Global: Pajson Agro India to Acquire Pacific Global FZCO, Adding 60,000 MT Capacity at the World’s Largest Cashew Origin

All-stock 100% acquisition | ₹354.52 crore | Board also approves ESOS 2026 New Delhi [India], November 6: Pajson Agro India Limited (PAJSON | 544657 | INE14LM01012), a vertically integrated cashew processing company with farm-gate sourcing across key producing origins and a growing consumer brand, ‘Royal Mewa’, has announced that its Board of Directors, has approved […]

Read More
Business Fredun Pharmaceuticals EBITDA Growth Fredun Pharmaceuticals H1 FY27 Results Fredun Pharmaceuticals Net Profit Fredun Pharmaceuticals Revenue Growth Indian pharmaceutical industry

Fredun Pharmaceuticals On A Growth Overdrive: Net Profit Soars 94%, Ebitda Rockets 92% And Revenue Surges 87% In H1 Fy27

Mumbai (Maharashtra) [India], November 6: Fredun Pharmaceuticals Limited (BSE – FREDUN | 539730), one of India’s leading pharmaceutical formulation manufacturing companies, has announced its unaudited financial results for Q2 & H1 FY27. The Company offers a diversified portfolio spanning generics, cosmeceuticals, nutraceuticals, mobility solutions, and animal healthcare products. Key Financial Highlights Standalone key Financial Highlights […]

Read More
Business

Patil Automation Marks a Strong First Half of FY27; Consolidated Revenue Up 37% YoY, Net Profit Up 48%

Mumbai (Maharashtra) [India], November 6: Patil Automation Limited (NSE: PATILAUTOM | INE17GV01016), a leading provider of turnkey welding, assembly and robotics-integrated automation solutions, has released its Unaudited Standalone and Consolidated Financial Results for the half year ended September 30, 2026, reporting broad-based growth across the group. Performance Snapshot – H1 FY27 H1 FY27 Key Financial […]

Read More